Rhizen Pharmaceuticals SA, an arm of Alembic Pharmaceuticals, has entered into an exclusive worldwide license agreement with Novartis for the development and commercialisation of a lead compound that could be used in the treatment of human airway disorders.
Alembic Pharma said in a regulatory filing that this pact was inked for the development and commercialisation of inhaled dual P13K-delta gamma inhibitor and its closely related compounds for various indications.
As per the agreement, Switzerland-based Rhizen will receive an upfront payment and is eligible to receive development, regulatory and sale milestones payments, it added. 
In addition, Rhizen is also eligible to receive tiered royalties on annual net sales.
The company said that the lead compound has demonstrated anti-inflammatory and immunomodulatory activity in pre clinical systems and models representative of respiratory diseases. It holds promise in the treatment of human airway disorders.
View Latest News:
- Nemesis Bioscience, a Biotech Business, has developed a New Weapon to fight against Superbugs
- Protein evolution undergoes a new makeover - designed for one only !
- ATP not only powers our body but chips too! Biological transistors in the making
- War against Botulism steps up to another level with unmasking the toxin's ability to stay assembled in one piece